THE FACT ABOUT NEW ADVANCEMENTS IN BRD4 INHIBITION THERAPY ABBV-744 THAT NO ONE IS SUGGESTING

In Section C, contributors will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will get treatment till sickness progression or perhaps the contributors are not able to tolerate the study drugs.- Participant eaten grapefruit or grapefruit solutions within 3 times ahead of the 1st dose o